EUVIMEDEUVIMED entdecken
Crossref

Plasma Proteomics for Risk Prediction and Therapeutic Target Discovery in Crohn’s Disease and Ulcerative Colitis

Xiaoqin Gan, Yanjun Zhang, Yuanyuan Zhang, Ziliang Ye, Sisi Yang, Hao Xiang, Yu Huang, Yiting Wu, Yiwei Zhang, Xianhui Qin iD

Inflammatory Bowel Diseases · 2026

DOI: 10.1093/ibd/izaf325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2026. Verfasst von Xiaoqin Gan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of …. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative, Proteomics, Biomarkers. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Key Research and Development Program of China, 2022YFC2009605, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We aimed to identify plasma proteins associated with incident Crohn’s disease (CD) and ulcerative colitis (UC), develop and validate predictive models for CD and UC risk, and uncover novel protein-based drug targets.

Methods

The study included 46 523 participants from England in the UK. Biobank as the development set and 47 105 participants for internal replication. An external validation set comprised 5807 participants from Scotland and Wales. Plasma proteomic profiling was performed on 2911 proteins.

Results

In the development set, 49 and 34 proteins were significantly associated with incident CD and UC risk, respectively (Bonferroni P < .05). These findings were replicated in the internal replication set. Two-sample Mendelian randomization (MR) analysis identified three proteins (TIMP1, TNFRSF10A, and LTBR) with causal associations for CD and four proteins (CCL20, OSM, NOS2, and CD300E) for UC. Among these, TIMP1 and CD300E represent novel, undrugged targets, while the remaining five are currently druggable. The proteomic-based model, incorporating age, sex, and candidate proteins, demonstrated strong predictive performance in the external validation set, with a C-index of 0.94 (95% CI, 0.88–1.00) for CD and 0.82 (95% CI, 0.73–0.92) for UC. Integrating candidate proteins or the top 10 proteins into clinically based models significantly enhanced risk prediction for both CD and UC.

Conclusions

This study identifies novel plasma protein associations with CD and UC, supported by genetic evidence, and highlights their potential as therapeutic targets. Plasma proteomics significantly improves risk prediction for incident CD and UC compared to traditional clinical models, offering new avenues for drug discovery and personalized risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseColitis, UlcerativeProteomicsBiomarkersBlood ProteinsHumansFemaleMaleAdultMiddle AgedRisk FactorsRisk AssessmentMendelian Randomization Analysis

Stichwörter der Autor:innen

C-indexCrohn’s diseaseMendelian randomizationproteomicsulcerative colitis

Substanzen

BiomarkersBlood Proteins

Autor:innen und Institutionen

  • Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Multi-organ Injury Prevention and Treatment, Guangdong Provincial Inst…

ORCID-Profile: Xianhui Qin

Förderung

  • National Key Research and Development Program of China
  • 2022YFC2009605
  • National Natural Science Foundation of China
  • Key Technologies R&D Program of Guangdong Province
  • Guangdong Provincial Clinical Research Center for Kidney Disease
  • Program of Introducing Talents of Discipline to Universities, 111 Plan
  • President Foundation of Nanfang Hospital, Southern Medical University
  • the Development and Reform Commission of Shenzhen Municipality

Zitieren

APA

Gan, X., Zhang, Y., Zhang, Y., Ye, Z., Yang, S., Xiang, H., Huang, Y., Wu, Y., Zhang, Y., & Qin, X. (2026). Plasma Proteomics for Risk Prediction and Therapeutic Target Discovery in Crohn’s Disease and Ulcerative Colitis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izaf325

Vancouver

Gan X, Zhang Y, Zhang Y, Ye Z, Yang S, Xiang H, et al. Plasma Proteomics for Risk Prediction and Therapeutic Target Discovery in Crohn’s Disease and Ulcerative Colitis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izaf325

BibTeX
@article{Gan2026,
  author = {Gan, Xiaoqin and Zhang, Yanjun and Zhang, Yuanyuan and Ye, Ziliang and Yang, Sisi and Xiang, Hao and Huang, Yu and Wu, Yiting and Zhang, Yiwei and Qin, Xianhui},
  title = {Plasma Proteomics for Risk Prediction and Therapeutic Target Discovery in Crohn’s Disease and Ulcerative Colitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izaf325}
}
Kostenlos starten →